• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心力衰竭合并常见细菌感染的住院患者:全国范围内艰难梭菌合并感染率及住院死亡率分析

Hospitalized Patients with Heart Failure and Common Bacterial Infections: A Nationwide Analysis of Concomitant Clostridium Difficile Infection Rates and In-Hospital Mortality.

作者信息

Mamic Petra, Heidenreich Paul A, Hedlin Haley, Tennakoon Lakshika, Staudenmayer Kristan L

机构信息

Department of Medicine, Stanford University School of Medicine, Stanford, California.

Department of Medicine, Stanford University School of Medicine, Stanford, California; VA Palo Alto Health Care System, Palo Alto, California; Stanford Cardiovascular Institute, Stanford, California.

出版信息

J Card Fail. 2016 Nov;22(11):891-900. doi: 10.1016/j.cardfail.2016.06.005. Epub 2016 Jun 16.

DOI:10.1016/j.cardfail.2016.06.005
PMID:27317844
Abstract

BACKGROUND

Patients with heart failure (HF) are frequently hospitalized with common bacterial infections. It is unknown whether they experience concomitant Clostridium difficile infection (CDI) more frequently than patients without HF, and whether CDI affects their mortality.

METHODS

We used 2012 National Inpatient Sample data to determine the rate of CDI and associated in-hospital mortality for hospitalized patients with comorbid HF and urinary tract infection (UTI), pneumonia (PNA), or sepsis. Univariate and multivariate analyses were performed. Weighted data are presented.

RESULTS

There were an estimated 5,851,582 patient hospitalizations with discharge diagnosis of UTI, PNA, or sepsis in 2012 in the United States. Of these, 23.4% had discharge diagnosis of HF. Patients with HF were on average older and had more comorbidities. CDI rates were higher in hospitalizations with discharge diagnosis of HF compared with those without HF (odds ratio 1.13, 95% confidence interval 1.10-1.16) after controlling for patient demographics and comorbidities and hospital characteristics. Among HF hospitalizations with UTI, PNA, or sepsis, those with concomitant CDI had a higher in-hospital mortality than those without concomitant CDI (odds ratio 1.81, 95% confidence interval 1.71-1.92) after controlling for the covariates outlined previously.

CONCLUSIONS

HF is associated with higher CDI rates among hospitalized patients with other common bacterial infections, even when adjusting for other known risk factors for CDI. Among these patients with comorbid HF, CDI is associated with markedly higher in-hospital mortality. These findings may suggest an opportunity to improve outcomes for hospitalized patients with HF and common bacterial infections, possibly through improved Clostridium difficile screening and prophylaxis protocols.

摘要

背景

心力衰竭(HF)患者常因常见细菌感染而住院。目前尚不清楚他们是否比无HF的患者更易发生艰难梭菌感染(CDI),以及CDI是否会影响其死亡率。

方法

我们使用2012年全国住院患者样本数据来确定合并HF及尿路感染(UTI)、肺炎(PNA)或脓毒症的住院患者的CDI发生率及相关住院死亡率。进行了单因素和多因素分析。呈现加权数据。

结果

2012年美国估计有5,851,582例患者因UTI、PNA或脓毒症出院诊断而住院。其中,23.4%有HF出院诊断。HF患者平均年龄更大,合并症更多。在控制患者人口统计学、合并症和医院特征后,有HF出院诊断的住院患者的CDI发生率高于无HF者(优势比1.13,95%置信区间1.10 - 1.16)。在因UTI、PNA或脓毒症住院的HF患者中,在控制上述协变量后,合并CDI者的住院死亡率高于未合并CDI者(优势比1.81,95%置信区间1.71 - 1.92)。

结论

即使在调整CDI的其他已知危险因素后,HF与其他常见细菌感染的住院患者中较高的CDI发生率相关。在这些合并HF的患者中,CDI与显著更高的住院死亡率相关。这些发现可能提示有机会改善合并HF及常见细菌感染的住院患者的预后,可能通过改进艰难梭菌筛查和预防方案来实现。

相似文献

1
Hospitalized Patients with Heart Failure and Common Bacterial Infections: A Nationwide Analysis of Concomitant Clostridium Difficile Infection Rates and In-Hospital Mortality.心力衰竭合并常见细菌感染的住院患者:全国范围内艰难梭菌合并感染率及住院死亡率分析
J Card Fail. 2016 Nov;22(11):891-900. doi: 10.1016/j.cardfail.2016.06.005. Epub 2016 Jun 16.
2
Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.2010年至2013年间艰难梭菌感染的负担:来自东欧一个学术中心的趋势和结果。
World J Gastroenterol. 2015 Jun 7;21(21):6728-35. doi: 10.3748/wjg.v21.i21.6728.
3
Impact of Clostridium difficile infection among pneumonia and urinary tract infection hospitalizations: an analysis of the Nationwide Inpatient Sample.艰难梭菌感染对肺炎和尿路感染住院患者的影响:一项基于全国住院患者样本的分析
BMC Infect Dis. 2015 Jul 1;15:254. doi: 10.1186/s12879-015-0925-9.
4
Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection.艰难梭菌感染住院成人的流行病学、结局及死亡预测因素
Intern Emerg Med. 2016 Aug;11(5):657-65. doi: 10.1007/s11739-015-1366-6. Epub 2015 Dec 22.
5
Clostridium difficile infection in patients hospitalized with type 2 diabetes mellitus and its impact on morbidity, mortality, and the costs of inpatient care.2型糖尿病住院患者的艰难梭菌感染及其对发病率、死亡率和住院护理费用的影响。
Diabetes Res Clin Pract. 2016 Jun;116:68-79. doi: 10.1016/j.diabres.2016.04.021. Epub 2016 Apr 24.
6
Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database.艰难梭菌感染与住院实体器官移植受者结局的关联:来自2009年全国住院患者样本数据库的结果
Transpl Infect Dis. 2012 Oct;14(5):540-7. doi: 10.1111/j.1399-3062.2012.00761.x. Epub 2012 Jun 22.
7
The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease.炎症性肠病成年住院患者艰难梭菌感染的发病率及转归
Scand J Gastroenterol. 2017 Nov;52(11):1240-1247. doi: 10.1080/00365521.2017.1362466. Epub 2017 Aug 6.
8
Risk, Outcomes, and Predictors of Infection in Lymphoma: A Nationwide Study.淋巴瘤感染的风险、结局及预测因素:一项全国性研究。
South Med J. 2018 Oct;111(10):628-633. doi: 10.14423/SMJ.0000000000000872.
9
Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.诊断医院获得性艰难梭菌感染后继续抗菌治疗的特征:对抗菌药物管理的意义。
Pharmacotherapy. 2012 Aug;32(8):744-54. doi: 10.1002/j.1875-9114.2012.01160.x.
10
The burden of Clostridium difficile in surgical patients in the United States.美国外科手术患者中艰难梭菌的负担。
Surg Infect (Larchmt). 2007 Dec;8(6):557-66. doi: 10.1089/sur.2006.062.

引用本文的文献

1
Role of gut microbiota and derived metabolites in cardiovascular diseases.肠道微生物群及其衍生代谢产物在心血管疾病中的作用。
iScience. 2025 Jul 30;28(9):113247. doi: 10.1016/j.isci.2025.113247. eCollection 2025 Sep 19.
2
Decoding the impact of gut microbiota on heart failure.解读肠道微生物群对心力衰竭的影响。
Genes Dis. 2025 Mar 6;12(6):101592. doi: 10.1016/j.gendis.2025.101592. eCollection 2025 Nov.
3
Gut Microbiota and Bacterial Extracellular Vesicles: Emerging Roles in Myocardial Remodelling and Cardiac Health.肠道微生物群与细菌细胞外囊泡:在心肌重塑和心脏健康中的新作用
J Extracell Biol. 2025 Aug 11;4(8):e70079. doi: 10.1002/jex2.70079. eCollection 2025 Aug.
4
Interactions between gut microbiota and cardiovascular drugs: effects on drug therapeutic effect and side effect.肠道微生物群与心血管药物之间的相互作用:对药物治疗效果和副作用的影响。
Front Cardiovasc Med. 2025 Jul 10;12:1570008. doi: 10.3389/fcvm.2025.1570008. eCollection 2025.
5
Recent advances on immunity and hypertension: the new cells on the kidney block.免疫与高血压的最新进展:肾脏中的新细胞阻滞
Am J Physiol Renal Physiol. 2025 Mar 1;328(3):F301-F315. doi: 10.1152/ajprenal.00309.2024. Epub 2025 Jan 24.
6
Role of Trimethylamine N-Oxide in Heart Failure.氧化三甲胺在心力衰竭中的作用。
Rev Cardiovasc Med. 2024 Jul 2;25(7):240. doi: 10.31083/j.rcm2507240. eCollection 2024 Jul.
7
Gut microbiota in heart failure and related interventions.心力衰竭中的肠道微生物群及相关干预措施。
Imeta. 2023 Jul 10;2(3):e125. doi: 10.1002/imt2.125. eCollection 2023 Aug.
8
": The Epidemiology of Toxigenic Strains in the Antibiotic Era-Insights from a Prospective Study at a Regional Infectious Diseases Hospital in Eastern Europe.:抗生素时代产毒菌株的流行病学——来自东欧一家地区传染病医院前瞻性研究的见解。
Antibiotics (Basel). 2024 May 17;13(5):461. doi: 10.3390/antibiotics13050461.
9
Role of gut microbiota in cardiovascular diseases - a comprehensive review.肠道微生物群在心血管疾病中的作用——综述
Ann Med Surg (Lond). 2023 Oct 18;86(3):1483-1489. doi: 10.1097/MS9.0000000000001419. eCollection 2024 Mar.
10
The Role of Gut Microbiota and the Potential Effects of Probiotics in Heart Failure.肠道微生物群的作用及益生菌对心力衰竭的潜在影响。
Medicina (Kaunas). 2024 Feb 4;60(2):271. doi: 10.3390/medicina60020271.